Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and Cyclosporine in Advanced Solid Tumors and Colorectal Cancer
NCT02188264Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in solid tumor and colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Aug 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02188264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188264.